Subgroup analyses of a phase 1/2 study of lenvatinib (E7080), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC)

被引：0
|
作者：
Ikeda, Masafumi
Ikeda, Kenji
Kudo, Masatoshi
Osaki, Yukio
Okusaka, Takuji
Tamai, Toshiyuki
Suzuki, Takuya
Hisai, Takashi
Miyagishi, Hideaki
Okita, Kiwamu
Kumada, Hiromitsu
机构：
[1] Natl Canc Ctr Hosp East, Dept Hepatobiliary & Pancreat Oncol, Chiba, Japan
[2] Toranomon Gen Hosp, Tokyo, Japan
[3] Kinki Univ, Sch Med, Osakasayama, Osaka, Japan
[4] Osaka Red Cross Hosp, Dept Gastroenterol & Hepatol, Osaka, Japan
[5] Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Tokyo, Japan
[6] Eisai & Co Ltd, Tokyo, Japan
[7] Shunan Mem Hosp, Kudamatsu, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 04期
关键词：
D O I：
10.1200/JCO.2017.35.4_suppl.309
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
309
引用
下载
收藏
页数：2
相关论文
共 50 条
  • [1] Phase I/II study of lenvatinib (E7080), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC): Phase I results
    Mitsunaga, Shuichi
    Ikeda, Masafumi
    Ueno, Hideki
    Nakachi, Kohei
    Morizane, Chigusa
    Kondo, Shunsuke
    Shimizu, Satoshi
    Kojima, Yasushi
    Suzuki, Takuya
    Tamai, Toshiyuki
    O'Brien, James P.
    Okusaka, Takuji
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [2] Phase I/II study of E7080 (lenvatinib), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC): Initial assessment of response rate.
    Okita, Kiwamu
    Kumada, Hiromitsu
    Ikeda, Kenji
    Kudo, Masatoshi
    Kawazoe, Seiji
    Osaki, Yukio
    Ikeda, Masafumi
    Tamai, Toshiyuki
    Suzuki, Takuya
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [3] PHASE I/II TRIAL OF LENVATINIB (E7080), A MULTI-TARGETED TYROSINE KINASE INHIBITOR, IN PATIENTS (PTS) WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC)
    Ikeda, K.
    Kumada, H.
    Kudo, M.
    Kawazoe, S.
    Osaki, Y.
    Ikeda, M.
    Okusaka, T.
    Suzuki, T.
    O'Brien, J. P.
    Okita, K.
    ANNALS OF ONCOLOGY, 2012, 23 : 244 - 244
  • [4] A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours
    Boss, D. S.
    Glen, H.
    Beijnen, J. H.
    Keesen, M.
    Morrison, R.
    Tait, B.
    Copalu, W.
    Mazur, A.
    Wanders, J.
    O'Brien, J. P.
    Schellens, J. H. M.
    Evans, T. R. J.
    BRITISH JOURNAL OF CANCER, 2012, 106 (10) : 1598 - 1604
  • [5] A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer
    Schlumberger, Martin
    Jarzab, Barbara
    Cabanillas, Maria E.
    Robinson, Bruce
    Pacini, Furio
    Ball, Douglas W.
    McCaffrey, Judith
    Newbold, Kate
    Allison, Roger
    Martins, Renato G.
    Licitra, Lisa F.
    Shah, Manisha H.
    Bodenner, Donald
    Elisei, Rossella
    Burmeister, Lynn
    Funahashi, Yasuhiro
    Ren, Min
    O'Brien, James P.
    Sherman, Steven I.
    CLINICAL CANCER RESEARCH, 2016, 22 (01) : 44 - 53
  • [6] A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours
    D S Boss
    H Glen
    J H Beijnen
    M Keesen
    R Morrison
    B Tait
    W Copalu
    A Mazur
    J Wanders
    J P O'Brien
    J H M Schellens
    T R J Evans
    British Journal of Cancer, 2012, 106 : 1598 - 1604
  • [7] A phase II trial of the multitargeted kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC).
    Schlumberger, Martin
    Jarzab, Barbara
    Cabanillas, Maria E.
    Robinson, Bruce
    Pacini, Furio
    Ball, Douglas Wilmot
    McCaffrey, Judith C.
    Newbold, Kate
    Allison, Roger
    Martins, Renato
    Licitra, Lisa F.
    Shah, Manisha H.
    Bodenner, Donald
    Elisei, Rossella
    Burmeister, Lynn A.
    Funahashi, Yasuhiro
    Sellecchia, Rita
    Andresen, Corina
    O'Brien, James P.
    Sherman, Steven I.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] A PHASE 2 TRIAL OF THE MULTITARGETED KINASE INHIBITOR LENVATINIB (E7080) IN PATIENTS (PTS) WITH RECURRENT GLIOBLASTOMA (GBM) AND DISEASE PROGRESSION FOLLOWING PRIOR BEVACIZUMAB TREATMENT
    Reardon, D. A.
    Pan, E.
    Fan, J.
    Mink, J.
    Barboriak, D. P.
    Vredenburgh, J. J.
    Desjardins, A.
    Peters, K.
    O'Brien, J. P.
    Wen, P. Y.
    ANNALS OF ONCOLOGY, 2012, 23 : 146 - 146
  • [9] A phase I study of E7080 in patients (pts) with advanced malignancies
    Glen, H.
    Boss, D. R.
    Morrison, R.
    Roelvink, M.
    Wanders, J.
    Mazur, A.
    Gupta, A.
    Das, A.
    Evans, T. R.
    Schellens, J. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] A PHASE IB CLINICAL TRIAL OF THE MULTITARGETED KINASE INHIBITOR LENVATINIB (E7080) IN COMBINATION WITH EVEROLIMUS FOR TREATMENT OF METASTATIC RENAL CELL CARCINOMA (RCC)
    Molina, A. M.
    Hutson, T. E.
    Larkin, J.
    Gold, A.
    Andresen, C.
    Wood, K.
    Motzer, R. J.
    Michaelson, M. D.
    ANNALS OF ONCOLOGY, 2012, 23 : 269 - 269
12345